Treatment of gestational trophoblastic disease in the 2020s.

Curr Opin Obstet Gynecol

Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London, UK.

Published: February 2021

Purpose Of Review: This review demonstrates the evidence for new systemic anticancer treatments and how they integrate within conventional management for gestational trophoblastic neoplasia (GTN). We present the evidence on atypical placental site nodules, and how they incorporate within the GTN spectrum, as well as updates regarding GTN staging and follow-up.

Recent Findings: First-line treatment for GTN still lies in conventional chemotherapy, although the introduction of anti-PD1/PD-L1 immune checkpoint inhibitors has shown significant promise in management of relapsed disease, with responses reported in multiple relapsed choriocarcinomas as well as epithelioid trophoblastic tumours and placental site trophoblastic tumours (ETT/PSTT). Following completion of treatment, ETT/PSTT still require life-long surveillance but for other GTN, no recurrences have been detected after 7 years.

Summary: Checkpoint inhibitors are likely to play an increasing role in the future management of GTN management. Further refinement of prognostic factors to identify those most at risk of GTN recurrence is warranted so that surveillance can be focussed on those most at risk, whilst minimizing unnecessary intervention for those at lower risk.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116872PMC
http://dx.doi.org/10.1097/GCO.0000000000000674DOI Listing

Publication Analysis

Top Keywords

gestational trophoblastic
8
placental site
8
checkpoint inhibitors
8
trophoblastic tumours
8
gtn
7
treatment gestational
4
trophoblastic
4
trophoblastic disease
4
disease 2020s
4
2020s purpose
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!